Explore the data on PentaHibe Base and PentaHibe Complete tested on different cell types for viability, recovery and proliferation.
Deep dive into the publications and download our protocols for guidance.
A ready-to-use cryopreservation medium containing 10% pentaisomaltose and 2% DMSO, PentaHibe Complete can be used with a range of cell types.
Objectives: to compare and evaluate the viability and recovery of T-cells purified from buffy coats after cryopreservation with a self-made 10% DMSO formulation, a commercial product with 10% DMSO, or ready-to-use PentaHibe Complete.
Results: T-cells purified from buffy coats from healthy donors and cryopreserved with PentaHibe Complete show similar viability and recovery to those cryopreserved with self-made and commercial formulas containing 10% DMSO.
Objectives: to compare and evaluate the proliferation of T-cells purified from buffy coats after cryopreservation with a self-made 10% DMSO formulation, a commercial product with 10% DMSO, and ready-to-use PentaHibe Complete.
Results: T-cells purified from buffy coats and cryopreserved with PentaHibe Complete show similar proliferation as those cryopreserved with self-made and commercial formulas containing 10% DMSO.
Objectives: to compare and evaluate the viability of adipose tissue derived human mesenchymal stem cells after cryopreservation with a self-made 10% DMSO formulation, a commercial product with 10% DMSO, or ready-to-use PentaHibe Complete.
Results: PentaHibe Complete is suitable for the cryopreservation of adipose tissue derived human mesenchymal stem cells.
Objectives: to compare and evaluate the viability and recovery of CHO cells after cryopreservation with a self-made 10% DMSO formulation, a commercial product with 10% DMSO, or ready-to-use PentaHibe Complete.
Results: CHO cells cryopreserved with PentaHibe Complete show similar viability and recovery to those cryopreserved with self-made and commercial formulas containing 10% DMSO.
A natural carbohydrate-based cryoprotective agent, PentaHibe Base is a safe and effective alternative to dimethyl sulfoxide (DMSO) for cryopreservation of cells.
The following data is an example of how to use PentaHibe Base as the sole CPA for cryopreservation of hematopoietic stem cells.
Objectives: to demonstrate that DMSO can be replaced with 16% PentaHibe Base as a safer cryoprotectant for the cryopreservation of peripheral blood stem cells.
Results: the recovery of viable CD34+ cells using PentaHibe Base is comparable to DMSO.
Note: The recovery of CD34+ cells from apheresis samples after thawing is expressed as the percentage of the number of CD34+ cells before cryopreservation. Each data point represents duplicate measurements for each donor.
Objectives: colony-forming cell (CFC) assays were set up to investigate whether HPCs in cryopreserved HPC(A) samples retained their hematopoietic potential and were able to produce cells of the myeloid and erythroid lineages.
Samples cryopreserved in either 10% DMSO or 16% PentaHibe Base contained viable HPCs with the potential to produce colonies of the CFU-E and BFU-E, CFU-G, CFU-M, CFU-GM, and CFU-GEMM lineages.
Results: HPC(A) samples cryopreserved in either PentaHibe Base or DMSO show comparable colony-forming potential.
In vivo study
Objectives: to measure hematopoietic engraftment of human CD45+ cells in 8-week peripheral blood samples from immunodeficient laboratory mice.
Engraftment was evaluated by flow cytometry, which was calculated as the frequency of human CD45+ cells in peripheral blood at 8 weeks post transplantation.
Results: Engraftment levels were comparable when using either PentaHibe Base or 10% DMSO at 8 weeks. No significant differences in the frequencies of human CD45+ cells in the samples cryopreserved in PentaHibe Base or DMSO.
Objectives: to measure hematopoietic engraftment of human CD45+ cells in 16-week bone barrow samples from immunodeficient laboratory mice.
Engraftment was evaluated by flow cytometry, which was calculated as the frequency of human CD45+ cells in bone marrow at 16 weeks post transplantation.
Results: Engraftment levels were comparable when using either PentaHibe Base or 10% DMSO at 16 weeks. No significant differences in the frequencies of human CD45+ cells in the samples cryopreserved in PentaHibe Base or DMSO.
Customize your own cryopreservation formulation with PentaHibe Base.
You can dilute according to your needs, add substances as required and decrease the need for DMSO down to only 1%.
Objectives: to evaluate the viability and recovery of T-cells after cryopreservation with RPMI-1640 media supplemented with 10% PentaHibe Base, 2% DMSO and 4% human albumin.
T-cells were isolated from buffy coats from healthy donors.
Results: T-cells cryopreserved with 10% PentaHibe Base in a custom-made formulation demonstrate good viability and recovery after thaw.
Objectives: to compare and evaluate the viability and recovery of T-cells after cryopreservation with a self-made 10% DMSO formulation, a commercial product with 10% DMSO, or a custom-made formulation containing 10% PentaHibe Base, 1% DMSO and 4% human albumin.
Results: T-cells cryopreserved with a custom-made formulation with 10% PentaHibe Base and only 1% DMSO show similar viability and recovery to self-made and commercial formulations with 10% DMSO.